Regulatory, legislative, and policy updates with anticoagulant use

被引：0
作者：
John Fanikos
Leo F. Buckley
Ahmed Aldemerdash
Kimberly J. Terry
Gregory Piazza
Jean M. Connors
Samuel Z. Goldhaber
机构：
[1] Brigham and Women’s Hospital,Department of Pharmacy Services
[2] Brigham and Women’s Hospital,Divisions of Cardiovascular Medicine, Department of Medicine
[3] Harvard Medical School,Divisions of Hematology, Department of Medicine
[4] Brigham and Women’s Hospital,undefined
[5] Harvard Medical School,undefined
来源：
Journal of Thrombosis and Thrombolysis | 2015年 / 39卷
关键词：
Venous thromboembolism; Stroke; Anticoagulation; Regulatory affairs; Health policy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Thromboembolism afflicts millions of patients annually in the United States and is associated with a significant cost burden. Recent advances in oral anticoagulation have provided clinicians with more options for management of these diseases. Accordingly, regulatory, legislative, and policy-making organizations have intervened with the aim of improving patient outcomes, ensuring patient safety, and reducing costs. There have been a number of recent developments in surveillance, litigation, and regulatory oversight that clinicians should recognize. In this review article we summarize key updates related to the management of anticoagulant therapy as it relates to thrombosis prevention and treatment.
引用
收藏
页码：273 / 287
页数：14
相关论文
共 91 条
[1]  
Roger VL(2012)Heart disease and stroke statistics-2012 update: a report from the American Heart Association Circulation 125 e2-e220
[2]  
Go AS(2006)Projected costs of ischemic stroke in the United States Neurology 67 1390-1395
[3]  
Lloyd-Jones DM(2012)Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates Thromb Haemost 108 291-302
[4]  
Brown DL(2014)Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985–2009) Am J Med 127 829-839
[5]  
Boden-Albala B(2014)Medication errors associated with anticoagulant therapy in the hospital Am J Cardiol 94 532-535
[6]  
Langa KM(2011)Anticoagulation-associated adverse drug events Am J Med 124 1136-1142
[7]  
Mahan CE(2012)Regulatory, policy and quality update for venous thromboembolism and stroke in United States hospitals Thromb Res 130 586-590
[8]  
Borrego ME(2012)Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review Med Care 50 466-478
[9]  
Woersching AL(2010)Accountability measures—using measurements to promote quality improvement N Engl J Med 363 683-688
[10]  
Huang W(2008)Hospital treatment of patients with ischemic stroke or transient ischemic attack using the “Get With The Guidelines” program Arch Intern Med 168 411-417
12345678910